Sengupta S, Velpandian T, Kabir S R, Gupta S K
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi.
Eur J Clin Pharmacol. 1998 Sep;54(7):541-7. doi: 10.1007/s002280050510.
The present study was conducted to compare the analgesic efficacy of a new topical gel formulation of nimesulide (10 mg of pure drug) with that of placebo, diclofenac and piroxicam gels (10 mg of pure drug) in three parallel groups in a double-blinded, randomized fashion with vehicle placebo. The analgesic activity of nimesulide was subsequently correlated with its pharmacokinetic profile.
The drugs were applied on a fixed marked area on the skin of the right forearm. Pain stimulus was administered using a modification of the Hollander method, before and at 15, 30, 60, 120 min and 240 min post-treatment. The pain experienced by the subjects was ranked separately on the visual analogue scale (VAS) and the ten-point category scale. Antinociception induced by the treatments was evaluated through the placebo-related ratings (PRR) and total pain relief (TOTPAR) analysis. The plasma concentration of nimesulide was estimated using high-performance liquid chromatography (HPLC).
Nimesulide exhibited better efficacy than diclofenac, piroxicam and placebo. It demonstrated faster onset of action in concordance with earlier studies. Peak analgesic effect was observed at 120 min post-treatment, which correlated with the pharmacokinetic profile of the drug in gel formulation. In this study, diclofenac was found to be superior to piroxicam though both drugs exhibited peak analgesic effect at 60 min post-treatment. In the modified Hollander method, a good correlation was found between the ten point category scale and the VAS, indicating that it may serve as a sensitive and reliable method for the screening of analgesic drugs.
The superior analgesic activity of nimesulide (as gel formulation), correlating with its pharmacokinetic profile, indicates that the topical route of administration may be a safe and effective alternative to the presently used oral and rectal routes.
本研究旨在以双盲、随机方式,将尼美舒利(10毫克纯药物)的新型外用凝胶制剂与安慰剂、双氯芬酸和吡罗昔康凝胶(10毫克纯药物)在三个平行组中进行比较,并设置赋形剂安慰剂。随后将尼美舒利的镇痛活性与其药代动力学特征相关联。
将药物涂抹于右前臂皮肤的固定标记区域。在治疗前以及治疗后15、30、60、120分钟和240分钟,采用改良荷兰法施加疼痛刺激。受试者所经历的疼痛分别在视觉模拟量表(VAS)和十点分类量表上进行评分。通过安慰剂相关评分(PRR)和总疼痛缓解(TOTPAR)分析评估治疗诱导的抗伤害感受。使用高效液相色谱法(HPLC)估算尼美舒利的血浆浓度。
尼美舒利表现出比双氯芬酸、吡罗昔康和安慰剂更好的疗效。与早期研究一致,其起效更快。在治疗后120分钟观察到峰值镇痛效果,这与该药物凝胶制剂的药代动力学特征相关。在本研究中,发现双氯芬酸优于吡罗昔康,尽管两种药物均在治疗后60分钟出现峰值镇痛效果。在改良荷兰法中,十点分类量表与VAS之间发现良好相关性,表明它可作为筛选镇痛药的灵敏且可靠的方法。
尼美舒利(作为凝胶制剂)的卓越镇痛活性与其药代动力学特征相关,表明局部给药途径可能是目前使用的口服和直肠给药途径的安全有效替代方案。